UNSPSC 51361601: Paraldehyde

This classification denotes an anticonvulsant, hypnotic, and sedative with the molecular formula C6H12O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S6M3YBG8QA, chemically known as 2,4,6-trimethyl-s-trioxane but generally known as paraldehyde, which bears US NIH Compound Identifier 31264. European Medicines Agency schedules Paraldehyde in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14774MIG.

World Health Organization schedules paraldehyde in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, PARALDEHYDE remains the US FDA Preferred Term for this commodity. SMILES: O1C(OC(OC1C)C)C.

UNSPSC 51361601 Paraldehyde is a Commodity code that, based on recent state and local opportunities, covers pharmaceutical products and related health-supply items procured by state agencies, counties, and cooperative purchasing alliances. The three recent opportunities posted under or near this code involve narcotics antagonists (naloxone), generic pharmaceuticals, and over-the-counter products — reflecting a broader scope than paraldehyde alone. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multi-state cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). These solicitations indicate that state and local governments use codes in this family to procure pharmaceuticals for public health, emergency response, employee health plans, and community care programs. Vendors must typically hold current Good Manufacturing Practices (cGMP) certification, comply with the Drug Supply Chain Security Act (DSCSA), maintain FDA clearance, and provide detailed product information including National Drug Codes (NDC) and expiration-date assurances.

Geographic activity centers on Florida, Texas, and Minnesota-based cooperative purchasing that serves multiple states including Oregon. The Seminole County, Florida IFB (Solicitation IFB60459723LAS) posted June 30, 2026, sought 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to Sanford, Florida, due July 26, 2023 — a past-due notice suggesting either archival data or posting error. The Texas HHS Commission issued an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. MMCAP's RFP (S1070000015802) posted January 20, 2026, with proposals due March 26, 2026, sought generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with awards effective July 1, 2026, and a two-year initial contract term. The MMCAP procurement weighted price competitiveness at 75 percent and requires vendors to maintain $5 million commercial general liability insurance and pay a 3 percent administrative fee on all contract purchases.